title: Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
abstract: We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Despite treatment-associated declines in total and cortical BMD, trabecular thinning and reduced trabecular bone volume, bone strength did not change significantly from baseline.
  
  
  BACKGROUND
  Teriparatide is an established anabolic therapy for osteoporosis; however, treatment effects at the distal radius are unclear. Therefore, we aimed to monitor changes in bone microarchitecture and estimated strength at the distal radius and tibia in osteoporotic postmenopausal women.
  
  
  METHODS
  We used high-resolution peripheral quantitative computed tomography (Scanco Medical, Switzerland) to perform a standard three-dimensional morphological analysis of the distal radius and tibia in 11 osteoporotic postmenopausal women (mean age, 68.7 ± 12.7 years) at baseline, 6, 12, and 18 months after initiation of 20 μg/day of teriparatide. Ten of the women received bisphosphonate therapy prior to starting on teriparatide. In addition to the standard analysis, we quantified cortical bone mineral density (BMD), porosity, and thickness using an automated segmentation procedure and estimated bone strength (ultimate stress) using finite element analysis.
  
  
  RESULTS
  After 18 months, we observed a decrease in total BMD (p = 0.03) at the distal radius and a decrease in cortical BMD at the distal radius (p = 0.05) and tibia (p = 0.01). The declines in cortical BMD were associated with trends for increased cortical porosity at both sites. At the distal radius, 18 months of teriparatide treatment was also associated with trabecular thinning (p = 0.009) and reduced trabecular bone volume ratio (p = 0.08). We observed similar trends at the distal tibia. Despite these changes in bone quality, bone strength was maintained over the 18-month follow-up.
  
  
  CONCLUSIONS
  The observed changes in cortical bone structure are consistent with the effects of parathyroid hormone on intracortical bone remodeling. Controlled trials involving larger sample sizes are required to confirm the effects of teriparatide therapy on trabecular and cortical microarchitecture in the peripheral skeleton.
authors.affiliation: Department of Mechanical and Manufacturing Engineering, Schulich School of Engineering, University of Calgary, 2500 University Drive, N.W., Calgary, AB, T2N 1N4, Canada.
authors.forename: H M
authors.initials: HM
authors.lastname: Macdonald
authors.forename: K K
authors.initials: KK
authors.lastname: Nishiyama
authors.forename: D A
authors.initials: DA
authors.lastname: Hanley
authors.forename: S K
authors.initials: SK
authors.lastname: Boyd
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011884:Radius / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D013314:Stress, Mechanical; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use*; D013977:Tibia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide
references.citation: Bone. 2001 Feb;28(2):150-9
references.pmid: 11182372
references.citation: Technol Health Care. 1998 Dec;6(5-6):329-37
references.pmid: 10100936
references.citation: Osteoporos Int. 1998;8(1):53-60
references.pmid: 9692078
references.citation: Bone. 2008 Jun;42(6):1203-13
references.pmid: 18358799
references.citation: J Biomech. 2001 Apr;34(4):513-7
references.pmid: 11266675
references.citation: J Bone Miner Res. 2002 Apr;17(4):687-94
references.pmid: 11918226
references.citation: Med Eng Phys. 2008 Jul;30(6):792-9
references.pmid: 18164643
references.citation: J Clin Endocrinol Metab. 2003 Mar;88(3):1150-6
references.pmid: 12629098
references.citation: CMAJ. 2006 Jul 4;175(1):52-9
references.pmid: 16818910
references.citation: N Engl J Med. 2001 May 10;344(19):1434-41
references.pmid: 11346808
references.citation: J Bone Miner Res. 2006 Nov;21(11):1785-90
references.pmid: 17002571
references.citation: J Bone Miner Res. 1999 Apr;14(4):536-45
references.pmid: 10234574
references.citation: J Biomech. 1995 Jan;28(1):69-81
references.pmid: 7852443
references.citation: J Bone Miner Res. 2009 Oct;24(10):1672-80
references.pmid: 19419306
references.citation: J Bone Miner Res. 2003 Mar;18(3):539-43
references.pmid: 12619939
references.citation: Bone. 2007 Oct;41(4):505-15
references.pmid: 17693147
references.citation: J Bone Miner Res. 2010 Apr;25(4):882-90
references.pmid: 19839766
references.citation: J Bone Miner Res. 2001 Jan;16(1):157-65
references.pmid: 11149480
references.citation: J Bone Miner Res. 2010 Mar;25(3):472-81
references.pmid: 19778182
references.citation: J Bone Miner Res. 2007 Sep;22(9):1426-33
references.pmid: 17547537